IP Library Patent Application 17585190
Patent Application
App. No. 17/585,190

METHOD OF INITIATING AND ESCALATING SOTALOL HYDROCHLORIDE DOSING

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/585,190
Abstract

The present invention provides novel methods of initiating and escalating sotalol hydrochloride in patients in need thereof.

Claims (14)

1 - 20 . (canceled)

21 . A method of escalating oral sotalol hydrochloride therapy, comprising:

identifying a subject:

(i) as having a creatinine clearance within a range of 10-90 mL/min;

(ii) as having had symptomatic atrial fibrillation or atrial flutter, wherein the subject is currently in sinus rhythm; and

(iii) as having received a prior oral dose of 120 mg of sotalol hydrochloride;

administering an intravenous (IV) dose of 105 mg of sotalol hydrochloride to the subject over a period of 1 hour to escalate the subject from the prior oral dose of 120 mg to a higher target oral dose of 160 mg.

22 . The method of claim 21 , wherein:

the subject is identified as non-renally impaired and as having a creatinine clearance in the range of 60-90 mL/min; or

the subject is identified as renally impaired as indicated by having a creatinine clearance in the range of 10-30 mL/min.

23 . The method of claim 22 , further comprising after the administering of the IV dose, administering a 160 mg oral dose of sotalol hydrochloride to the non-renally impaired subject or to the renally impaired subject.

24 . The method of claim 23 , further comprising administering a second 160 mg oral dose of sotalol hydrochloride to the non-renally impaired subject or to the renally impaired subject.

25 . The method of claim 24 , wherein the subject is identified as renally impaired and as having a creatinine clearance in the range of 10-30 mL/min.

26 . The method of claim 24 , wherein the subject is identified as non-renally impaired and as having a creatinine clearance in the range of 60-90 mL/min.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2022
From: SOMBERG, JOHN CHARIN; KASHFIAN, BRANDON IRA; MOLNAR, JANOS
To: ALTATHERA PHARMACEUTICALS LLC
Reel/Frame 059333/0883 →